Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) reported a Q3 loss narrower than the loss expected by analysts despite revenues that fell short of expectations. The company reported a Q3 loss of $0.27 per share, narrower than the loss of $0.36 a year ago and narrower than the loss of $0.29 predicted by analysts. Total revenues of $14.68 million were down from $16.73 million in Q3 2013 and missed analyst estimates of $16.26 million. Iclusig, a kinase inhibitor which targets an abnormal tyrosine kinase expressed in leukemia, generated revenues of $14.5 million, an increase of 22% from the Q2 2014.Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) now expects research and development expenses of $125 million to $130 million, down from previous guidance of $140 million to $150 million for 2014. Cash used in operations in 2014 is now expected to range from $150 million to $155 million, compared to previous guidance of $165 million to $175 million. Shares of ARIA are trading within a 52-week range of $2.21 - $9.83.WellCare Health Plans, Inc. (NYSE:WCG) reported Wednesday better-than-expected financial results and issued mixed guidance for Q4, with EPS below Street forecasts and revenues above the consensus. Q3 adjusted net income was $0.77 per diluted share, excluding a $0.18 reduction in the Windsor bargain purchase gain, compared to $1.56 per diluted share in the year-ago period. Analysts were expecting EPS of $0.69 per share. Revenues climbed 32% year-on-year to $3.3 billion, slightly above the consensus of $3.28 billion.Membership, as of September 30, increased 43% year-on-year to 4.0 million. WellCare Health Plans, Inc. (NYSE:WCG) said Medicaid Health Plans segment membership rose by 495,000 or 28% year-on-year to 2.3 million members as of the end of September. WellCare Health said it expects Q4 EPS of $0.60-$0.70, below the consensus of $0.72 and quarterly revenues of $3.3 billion-$3.4 billion, above the Street forecast of $3.27 billion. The company said it expects to issue FY2015 guidance during its Q4 2014 earnings call. WCG shares have a 52-week range of $55.16-$78.37.Cognizant Technology Solutions Corp (NASDAQ:CTSH) a provider of information technology, consulting, and outsourcing, announced Q3 results that beat the Street view on EPS and met total revenues on a year-over-year increase. Cognizant Technology Solutions Corp (NASDAQ:CTSH) reported Q3 adjusted EPS of $0.66, up from $0.59 in the year-ago period and beating analyst estimates of $0.63. Total revenues of $2.58 billion were up from $2.30 billion in Q3 2013 and in line with analyst projections of $2.56 billion.The company provided Q4 guidance and expects revenue expected to be between $2.61 billion and $2.64 billion and non-GAAP diluted EPS of at least $0.63. The Street consensus is $2.59 billion in revenue and earnings of $0.64 per share. Full-year revenue is expected to be between $10.13 billion and $10.16 billion and full-year non-GAAP diluted EPS is expected to be at least $2.57, up from previous guidance of at least $2.54. The Street is at $10.1 billion in revenue and earnings of $2.54 per share. Shares of CTSH are at $48.49 within a 52-week range of 41.51 - 54.00.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
